Schistosoma mansoni: Genetic Complementation Analysis Shows That Two Independent Hycanthone/Oxamniquine-Resistant Strains Are Mutated in the Same Gene

Pica‐Mattoccia, Livia; Dias, Luiz Cândido de Souza; Moroni, Rolando; Cioli, Donato

doi:10.1006/expr.1993.1104

Cited by 50 publications

(36 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This strongly suggests that resistance is induced rather than selected from preexisting forms (16). The crossbreeding experiments of Cioli et al (23,25) and Pica-Mattocia et al (107) have clearly shown that oxamniquine resistance is controlled by a single autosomal recessive gene. Resistance to oxamniquine does not appear to spread easily within communities but, rather, tends to remain limited to individual cases.…”

Section: Genetics Of Drug Resistancementioning

confidence: 97%

Drug Resistance in Human Helminths: Current Situation and Lessons from Livestock

Geerts

Gryseels

2000

Clinical Microbiology Reviews

231

130

View full text Add to dashboard Cite

Section: Genetics Of Drug Resistancementioning

confidence: 97%

Drug Resistance in Human Helminths: Current Situation and Lessons from Livestock

Geerts

Gryseels

2000

Clinical Microbiology Reviews

231

130

View full text Add to dashboard Cite

“…Activity of oxamniquine is only confined to Schistosoma mansoni and it is hard to procure as well as more expensive than praziquantel ). In addition, reports on resistance to oxamniquine were quite striking where resistant schistosomes were able to survive drug doses 1,000-fold higher than the effective dose against sensitive parasites (Pica-Mattoccia et al 1993). Artemisinin derivatives, antimalarial drugs, are principally active against juvenile schistosomes and proved as effective prophylactics in endemic areas; however, their use in areas where schistosomiasis and malaria are co-endemic has many restrictions to avoid the development of resistance to the latter (Utzinger et al 2003).…”

Section: Introductionmentioning

confidence: 98%

Experimentally promising antischistosomal drugs: a review of some drug candidates not reaching the clinical use

2009

View full text Add to dashboard Cite

Schistosomiasis is a chronic parasitic disease affecting about 207 million people in the world. It still represents a major health problem in many tropical and sub-tropical countries as well as for travelers from developed countries. Control of the disease depends mainly on chemotherapy, with praziquantel becoming the exclusive drug. Extensive use of praziquantel with concerns about the possibility of drug resistance development, unavailability of an applicable vaccine, and the absence of a reasonable alternative to praziquantel all represent a real challenge. One of the suggested solutions is to exploit the advantages of compounds that proved efficacious at the experimental level with a good safety profile. These may undergo further investigations for the sake of developing their antischistosomal properties or to incorporate them in combination therapies. Chemotherapy literature is redundant with a huge number of compounds screened for their schistosomicidal properties. However, only a few of these may act as drug leads that could be promising in the development of a therapeutic reserve for schistosomiasis. The present paper reviews previous studies carried out on some of these compounds.

show abstract

“…Two years later, a group of scientists from Italy analyzed the genetic behavior responsible for oxamniquine resistant strains. Their results showed that schistosomes sensitivity to the drug was strictly related to specific chromosome(s) in a dominant gene encoding the enzyme that converts the drug to reactive ester [165] .…”

Section: Other Anti-parasitic Drugsmentioning

confidence: 99%

Gene mutations in parasitic diseases Part II: Parasite gene mutations

Abaza

El-Tonsy

2017

Parasitologists United Journal

View full text Add to dashboard Cite

Gene mutation may occur either in the parasite or in the host, which may be beneficial or harmful for each. As we previously discussed, part I covered causes and types of gene mutations as well as their relation(s) to or effect(s) on parasitic diseases; part II deals with parasite gene mutations. The most apparent manifestation is drug resistance especially with anti-malarial drugs for falciparum malaria. The majority of P. falciparum isolates are able to undergo gene mutations in genes encoding enzymes that control drug uptake. Parasite gene mutations are suggested to influence parasite virulence in toxoplasmosis and malignant malaria, and to have impact on the occurrence of malignancy in schistosomiasis and clonorchiasis. It is intended in the present review to present mechanism(s) of drug resistance due to parasite gene mutations, with special emphasis on anti-malarial drugs, albendazole, metronidazole, and other drugs used in treatment of African trypanosomiasis and toxoplasmosis. The review also presents other effects of parasite gene mutations on disease outcome and progress as well as occurrence of false diagnosis in falciparum malaria using ICTs utelizing histidine rich protein.

show abstract

Schistosoma mansoni: Genetic Complementation Analysis Shows That Two Independent Hycanthone/Oxamniquine-Resistant Strains Are Mutated in the Same Gene

Cited by 50 publications

References 0 publications

Drug Resistance in Human Helminths: Current Situation and Lessons from Livestock

Drug Resistance in Human Helminths: Current Situation and Lessons from Livestock

Experimentally promising antischistosomal drugs: a review of some drug candidates not reaching the clinical use

Gene mutations in parasitic diseases Part II: Parasite gene mutations

Contact Info

Product

Resources

About